Analysts see $3B potential in Sanofi-Regeneron cholesterol drug alirocumab

09/26/2013 | Reuters

Sanofi and Regeneron Pharmaceuticals' late-stage cholesterol therapy candidate alirocumab has the potential to become a blockbuster with more than $3 billion in sales, analysts said. Alirocumab belongs to a class of drugs called PCSK9 inhibitors. Deutsche Bank analysts said peak annual sales of alirocumab could reach exceed $3 billion, and BioMedTracker, an independent research firm, predicted sales of $3.7 billion by 2023.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID